(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 November 2023 (09.11.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/215267 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/34* (2017.01)
A61K 39/00 (2006.01) *A61K 47/18* (2017.01)
A61K 47/10 (2017.01) *A61K 47/26* (2006.01)

(21) International Application Number:
PCT/US2023/020660

(22) International Filing Date:
02 May 2023 (02.05.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/337,532 02 May 2022 (02.05.2022) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventor: **TANG, Xiaolin**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **TERMES, Lance A.**; Schwabe, Williamson & Wyatt PC, 1211 SW 5th Ave., Suite 1900, Portland, Oregon 97204 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

WO 2023/215267 A1

(54) Title: ANTI-INTERLEUKIN-4 RECEPTOR (IL-4R) ANTIBODY FORMULATIONS

(≥10μm) #/Container by microscopic method

5°C,	PEG 3350 Conc. (w/v)			Poloxamer 188 Conc. (w/v)		
Months	0.02%	0.04%	0.1%	0.02%	0.04%	0.1%
6	15	38	99	36	34	84
12	23	61	36	42	25	34
18	25	42	38	86	40	114
24	61	103	57	91	105	143
36	25	17	38	32	19	67

(≥25μm) #/Container by microscopic method

5°C,	PEG 3350 Conc. (w/v)			Poloxamer 188 Conc. (w/v)		
Months	0.02%	0.04%	0.1%	0.02%	0.04%	0.1%
6	0	11	42	17	2	19
12	6	19	11	17	8	4
18	8	6	11	21	4	30
24	8	13	11	11	15	15
36	15	0	6	2	4	17

FIG. 1

(57) Abstract: Pharmaceutical formulations comprising an antibody that specifically binds to human interleukin-4 receptor alpha (hIL-4Rα) are provided. The formulations may contain, in addition to an anti-IL-4Rα antibody, one or more buffers, at least one amino acid, at least one sugar, and a surfactant comprising a polyethylene glycol or a poloxamer. In one aspect, the pharmaceutical formulations do not have appreciable subvisible particle formation in the presence of lipase, and exhibit a substantial degree of antibody stability during storage and after being subjected to thermal and other physical stresses.

[Continued on next page]

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*